These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

190 related items for PubMed ID: 3032613

  • 1. Comparative in vitro activity of LY146032 (daptomycin) against gram-positive cocci.
    Machka K, Braveny I.
    Eur J Clin Microbiol; 1987 Feb; 6(1):96-9. PubMed ID: 3032613
    [Abstract] [Full Text] [Related]

  • 2. In-vitro susceptibility of gram-positive cocci to LY146032 teicoplanin, sodium fusidate, vancomycin, and rifampicin.
    Pohlod DJ, Saravolatz LD, Somerville MM.
    J Antimicrob Chemother; 1987 Aug; 20(2):197-202. PubMed ID: 2822646
    [Abstract] [Full Text] [Related]

  • 3. In vitro activity of LY146032 (daptomycin) against selected aerobic bacteria.
    Jorgensen JH, Maher LA, Redding JS.
    Eur J Clin Microbiol; 1987 Feb; 6(1):91-6. PubMed ID: 3032612
    [Abstract] [Full Text] [Related]

  • 4. Comparative in vitro activity of LY146032 (daptomycin), a new lipopeptide antimicrobial.
    Hodinka RL, Jack-Wait K, Wannamaker N, Walden TP, Gilligan PH.
    Eur J Clin Microbiol; 1987 Feb; 6(1):100-3. PubMed ID: 3032607
    [Abstract] [Full Text] [Related]

  • 5. Comparative in-vitro activity of LY146032 and eight other antibiotics against gram-positive bacteria isolated from children.
    Kline MW, Mason EO, Kaplan SL, Lamberth LB, Johnson GS.
    J Antimicrob Chemother; 1987 Aug; 20(2):203-7. PubMed ID: 2822647
    [Abstract] [Full Text] [Related]

  • 6. In vitro activity of LY146032 (daptomycin), a new peptolide.
    Ehlert F, Neu HC.
    Eur J Clin Microbiol; 1987 Feb; 6(1):84-90. PubMed ID: 3032611
    [Abstract] [Full Text] [Related]

  • 7. In vitro activity of the new glycopeptide decaplanin.
    Neu HC, Chin NX, Niu WW.
    Eur J Clin Microbiol Infect Dis; 1992 May; 11(5):458-62. PubMed ID: 1330562
    [Abstract] [Full Text] [Related]

  • 8. Comparative in vitro activities of teicoplanin, daptomycin, ramoplanin, vancomycin, and PD127,391 against blood isolates of gram-positive cocci.
    Shonekan D, Mildvan D, Handwerger S.
    Antimicrob Agents Chemother; 1992 Jul; 36(7):1570-2. PubMed ID: 1324649
    [Abstract] [Full Text] [Related]

  • 9. Antimicrobial susceptibility of Gram-positive bacterial isolates from the Asia-Pacific region and an in vitro evaluation of the bactericidal activity of daptomycin, vancomycin, and teicoplanin: a SENTRY Program Report (2003-2004).
    Biedenbach DJ, Bell JM, Sader HS, Fritsche TR, Jones RN, Turnidge JD.
    Int J Antimicrob Agents; 2007 Aug; 30(2):143-9. PubMed ID: 17531446
    [Abstract] [Full Text] [Related]

  • 10. In-vitro activity of LY146032 against Staphylococcus aureus and S. epidermidis.
    Coudron PE, Johnston JL, Archer GL.
    J Antimicrob Chemother; 1987 Oct; 20(4):505-11. PubMed ID: 2824426
    [Abstract] [Full Text] [Related]

  • 11. Comparative in vitro activity of daptomycin (LY146032) and vancomycin against gram-positive cocci determined using a pharmacokinetic model.
    Blenkharn JI, Darrell JH.
    Eur J Clin Microbiol Infect Dis; 1989 Aug; 8(8):734-7. PubMed ID: 2550236
    [Abstract] [Full Text] [Related]

  • 12. In vitro activity of LY146032, a new lipopeptide antibiotic, against gram-positive cocci.
    Verbist L.
    Antimicrob Agents Chemother; 1987 Feb; 31(2):340-2. PubMed ID: 3032099
    [Abstract] [Full Text] [Related]

  • 13. In-vitro activity of vancomycin, teicoplanin, daptomycin, ramoplanin, MDL 62873 and other agents against staphylococci, enterococci and Clostridium difficile.
    Bartoloni A, Colao MG, Orsi A, Dei R, Giganti E, Parenti F.
    J Antimicrob Chemother; 1990 Nov; 26(5):627-33. PubMed ID: 1688341
    [Abstract] [Full Text] [Related]

  • 14. Antimicrobial activity of everninomicin against clinical isolates of Enterococcus spp., Staphylococcus spp., and Streptococcus spp. tested by Etest.
    Terakubo S, Takemura H, Yamamoto H, Ikejima H, Kunishima H, Kanemitsu K, Kaku M, Shimada J.
    J Infect Chemother; 2001 Dec; 7(4):263-6. PubMed ID: 11810596
    [Abstract] [Full Text] [Related]

  • 15. Comparative bactericidal activities of daptomycin, glycopeptides, linezolid and tigecycline against blood isolates of Gram-positive bacteria in Taiwan.
    Huang YT, Liao CH, Teng LJ, Hsueh PR.
    Clin Microbiol Infect; 2008 Feb; 14(2):124-9. PubMed ID: 18076671
    [Abstract] [Full Text] [Related]

  • 16. Activity of LY146032 compared with that of methicillin, cefazolin, cefamandole, cefuroxime, ciprofloxacin, and vancomycin against staphylococci as determined by kill-kinetic studies.
    Stratton CW, Liu C, Weeks LS.
    Antimicrob Agents Chemother; 1987 Aug; 31(8):1210-5. PubMed ID: 2820300
    [Abstract] [Full Text] [Related]

  • 17. Comparative in-vitro activity of LY146032 a new peptolide, with vancomycin and eight other agents against gram-positive organisms.
    Benson CA, Beaudette F, Trenholm G.
    J Antimicrob Chemother; 1987 Aug; 20(2):191-6. PubMed ID: 2822645
    [Abstract] [Full Text] [Related]

  • 18. [In vitro activity of vancomycin and teicoplanin against gram-positive cocci].
    Bezian MC, Ribou G, Masquelier B.
    Pathol Biol (Paris); 1992 May; 40(5):461-5. PubMed ID: 1386667
    [Abstract] [Full Text] [Related]

  • 19. Comparative in-vitro activities of quinupristin-dalfopristin against Gram-positive bloodstream isolates.
    Schouten MA, Hoogkamp-Korstanje JA.
    J Antimicrob Chemother; 1997 Aug; 40(2):213-9. PubMed ID: 9301986
    [Abstract] [Full Text] [Related]

  • 20. LY146032: activity and resistance development in vitro.
    Mouton RP, Mulders SL.
    J Antimicrob Chemother; 1987 Oct; 20(4):513-7. PubMed ID: 2824427
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.